Evidence map›Paper›PMID 42306952›Full record

ArticleBiomolecules & biomedicine2026

Vojin Vukovic, Teodora Karan-Djurasevic, Darko Antic, Natasa Tosic, Irena Marjanovic, Branka Zukic, Ivana Grubisa, Tamara Bibic, Kristina Tomic Vujovic, Vladimir Otasevic and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Vojin VukovicClinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia; School of Medicine, University of Belgrade, Belgrade, Serbia.
Teodora Karan-DjurasevicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Darko AnticClinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia; School of Medicine, University of Belgrade, Belgrade, Serbia.
Natasa TosicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Irena MarjanovicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Branka ZukicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Ivana GrubisaInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
Tamara BibicClinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia.
Kristina Tomic VujovicClinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia.
Vladimir OtasevicClinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia.
Sofija KozaracClinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia.
Jelena IvanovicClinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia.
Sonja PavlovicClinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia.
Biljana MihaljevicClinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia; School of Medicine, University of Belgrade, Belgrade, Serbia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fludarabine treatment in patients with chronic lymphocytic leukemia (CLL) has been associated with immune dysregulation and the development of autoimmune hemolytic anemia (AIHA). Prior research indicates a potential correlation between the expression of the SLC28A3 gene, which encodes human concentrative nucleoside transporter 3 (responsible for fludarabine uptake), and treatment response. This retrospective study investigated the relationship between baseline SLC28A3 expression levels, quantified via reverse-transcriptase polymerase chain reaction (qRT-PCR), and the incidence of AIHA in a cohort of CLL patients receiving fludarabine and cyclophosphamide (FC) therapy. Patients were categorized into two groups: "FC-emergent AIHA," encompassing patients who developed AIHA during or following FC therapy, and "no FC-emergent AIHA," which included patients with pre-existing AIHA prior to any treatment and those who remained AIHA-free throughout follow-up. A comparative analysis of these groups revealed no significant differences in most clinical and biological variables. However, a statistically significant difference was observed in median baseline SLC28A3 expression, which was sevenfold lower in the "FC-emergent AIHA" group compared to the "no FC-emergent AIHA" group. Furthermore, SLC28A3 expression did not significantly correlate with most of the other clinical or biological parameters, including time to first treatment or overall survival. These findings suggest that diminished baseline SLC28A3 expression may correlate with an elevated risk of fludarabine-emergent AIHA in CLL patients. Further validation through larger, prospective cohorts is essential to confirm the predictive utility of SLC28A3 expression for optimizing fludarabine-based therapeutic strategies.

Indexed as

Anemia, Hemolytic, AutoimmuneLeukemia, Lymphocytic, Chronic, B-CellMembrane Transport ProteinsVidarabineAgedCyclophosphamideFemaleHumansMaleMiddle AgedRetrospective Studiescif nucleoside transporterCyclophosphamidefludarabineMembrane Transport ProteinsVidarabine

Identifiers

PMID42306952
PMCPMC13667957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.